Geron Corporation  

(Public, NASDAQ:GERN)   Watch this stock  
Find more results for GERN
2.59
-0.13 (-4.78%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.57 - 2.70
52 week 1.27 - 7.79
Open 2.70
Vol / Avg. 3.28M/6.23M
Mkt cap 406.47M
P/E     -
Div/yield     -
EPS -0.26
Shares 156.94M
Beta 1.70
Inst. own 53%
Aug 4, 2014
Q2 2014 Geron Earnings Release (Estimated) Add to calendar
Jul 8, 2014
Geron Corp at Piper Jaffray Catalyst Symposium
Jun 4, 2014
Geron at Jefferies Global Healthcare Conference - Webcast
May 20, 2014
Geron 2014 Annual Meeting of Stockholders - Webcast
May 15, 2014
Geron at Bank of America Merrill Lynch Health Care Conference - Webcast
May 1, 2014
Q1 2014 Geron Earnings Conference Call - Webcast
May 1, 2014
Q1 2014 Geron Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -1780.59% -2991.35%
Operating margin -1841.98% -3036.48%
EBITD margin - -2897.58%
Return on average assets -30.40% -45.92%
Return on average equity -32.14% -52.79%
Employees 46 -
CDP Score - -

Address

SUITE 2070, 149 COMMONWEALTH DRIVE
MENLO PARK, CA 94025
United States - Map
+1-650-4737700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets.

Officers and directors

Hoyoung Huh Ph.D Chairman of the Board
Age: 44
Bio & Compensation  - Reuters
John A. Scarlett M.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Olivia K. Bloom Chief Financial Officer, Executive Vice President - Finance, Treasurer
Age: 44
Bio & Compensation  - Reuters
Stephen N. Rosenfield J.D. Executive Vice President, General Counsel and Corporate Secretary
Age: 63
Bio & Compensation  - Reuters
Andrew J. Grethlein Ph.D. Executive Vice President - Technical Operations
Age: 48
Bio & Compensation  - Reuters
Melissa A. Kelly Behrs Executive Vice President - Portfolio and Alliance Management
Age: 49
Bio & Compensation  - Reuters
Craig C. Parker Executive Vice President - Corporate Development and Scientific Affairs
Bio & Compensation  - Reuters
Susan M. Molineaux Ph.D. Director
Age: 59
Bio & Compensation  - Reuters
Daniel M. Bradbury Independent Director
Bio & Compensation  - Reuters
Karin Eastham CPA Independent Director
Age: 64
Bio & Compensation  - Reuters